
News
Can semaglutide slow ageing? What the new study actually shows
A recent study associated semaglutide treatment with a slower progression of certain epigenetic markers of ageing. The results are promising, but they must be interpreted with caution. In this article, we explain what epigenetic clocks are, what the study measured, and which limitations need to be considered.
Patient guide
Semaglutide is known primarily for its role in treating type 2 diabetes and managing obesity. Its effects on weight, blood glucose, and cardiovascular risk are already documented, but researchers are investigating whether its metabolic benefits might also influence biological processes associated with ageing.
A study published in Nature Communications in 2026 drew attention after semaglutide treatment was associated with more favourable changes in several “epigenetic clocks.” Subsequent headlines suggested that the medication might slow ageing. The finding is worth discussing, but with one important distinction: a change in a biomarker is not equivalent to rejuvenating the body or demonstrably extending lifespan.
Key points
- The study identified favourable changes in certain epigenetic markers, not a demonstrated reversal of ageing.
- The research included a small and highly specific group: people with HIV and associated lipohypertrophy.
- Semaglutide is not currently an anti-ageing treatment and should be prescribed only for well-established medical indications.
In this article
01
What does “epigenetic age” mean?
Chronological age is the number of years that have passed since birth. Biological age attempts to describe how “aged” the body is from a functional and molecular perspective. The two are not necessarily identical: people of the same age may have very different metabolic, cardiovascular, and functional profiles.
Epigenetic clocks estimate certain components of ageing by analysing DNA methylation—chemical marks that influence how genes are switched on or off without changing the DNA sequence. Some clocks estimate biological age, others were developed to reflect the risk of disease or death, while the DunedinPACE marker attempts to measure the rate at which ageing occurs.
These tools are valuable in research, but they do not yet provide a clinical “verdict” on a person’s longevity. Results may vary depending on the algorithm used, and we do not yet know to what extent a short-term change in such a marker translates into fewer diseases or a longer life.

02
What did the study find?
The analysis included 84 adults with HIV and associated lipohypertrophy: 45 received semaglutide and 39 received placebo for 32 weeks. Researchers compared blood samples collected before and after the intervention using 17 clocks based on DNA methylation. The epigenetic analysis was conducted subsequently and was not a prespecified objective of the original study.
Compared with placebo, semaglutide was associated with a slower progression across several epigenetic clocks. DunedinPACE indicated an approximately 9% slower rate of ageing, while other tools, including PhenoAge, PCGrimAge, and OMICmAge, showed changes in the same direction.
One possible explanation is an improvement in factors that can accelerate biological ageing: visceral adiposity, chronic inflammation, and metabolic stress. However, the study cannot establish with certainty whether the effects were caused directly by semaglutide, by weight loss, by reduced visceral fat, or by a combination of these mechanisms.

03
Why can we not yet call it an anti-ageing treatment?
The results come from an exploratory analysis conducted after the completion of a study whose primary objective had been to reduce visceral adipose tissue. The sample was modest, the follow-up period was only 32 weeks, and the participants had HIV and lipohypertrophy—a context associated with chronic inflammation and accelerated biological ageing. The conclusions cannot automatically be applied to the general population.
In addition, not all epigenetic clocks responded in the same way. This increases the possibility that some results occurred by chance. The authors themselves emphasise the need for larger studies designed specifically to assess ageing and long enough to track clinically relevant outcomes.
Semaglutide is currently authorised for the control of type 2 diabetes and, in the appropriate formulation and for the corresponding indications, for weight management in eligible people. Slowing ageing is not an approved therapeutic indication.

Final takeaway
Conclusion
The study offers an interesting perspective: improving metabolic health with semaglutide might also influence certain molecular processes associated with ageing. However, it does not demonstrate that the medication rejuvenates the body, extends life, or prevents age-related diseases in the general population.
The important message is not that semaglutide represents a new “shortcut” to longevity. Rather, the research shows how closely visceral adiposity, inflammation, metabolism, and biological ageing are connected. Until dedicated studies and long-term clinical outcomes are available, the treatment should be used for its validated medical indications following an individual assessment.
Medical information notice
This material is for informational purposes and does not replace a medical consultation, diagnosis, or personalised recommendation from a doctor.
Frequently asked questions
Can I take semaglutide to slow ageing?
No. Semaglutide is not currently approved as an anti-ageing treatment. It should be prescribed only when there is a valid medical indication, following an assessment of the benefits, risks, and contraindications.
Do the results mean that semaglutide can make us younger?
No. The study identified changes in certain molecular markers associated with ageing, not organ rejuvenation or a demonstrated extension of lifespan.
If I have obesity or diabetes, do these results change the recommended treatment?
For now, they do not change the therapeutic indications. Treatment decisions are based on the diagnosis, metabolic risk, medical history, the patient’s goals, and the safety profile—not on the promise of an anti-ageing effect.
Medical sources
- 1Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy
Nature Communications, 2026
- 2Indicațiile terapeutice pentru Wegovy
European Medicines Agency.
- 3Indicațiile terapeutice pentru Ozempic
European Medicines Agency.